2025 Q3 -tulosraportti
84 päivää sittenTarjoustasot
First North Sweden
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr, FactSet| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 26.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 7.11.2025 | |
| 2025 Q2 -tulosraportti | 23.7.2025 | |
| 2024 Q4 -tulosraportti | 13.2.2025 | |
| 2024 Q2 -tulosraportti | 26.7.2024 | |
| 2023 Q4 -tulosraportti | 15.2.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·19 t sitten · MuokattuInterview with CEO, dated: For those unfamiliar with Prostatype Genomics – can you briefly describe the company, your business model, and the role you play in prostate cancer diagnostics and precision medicine? Prostatype Genomics is a company that originated as a spin-off from Karolinska Institutet in Stockholm and is active in precision medicine with a focus on prostate cancer. Our product is used after prostate cancer has been diagnosed and addresses one of the biggest clinical challenges globally: to determine which patients need to be treated with, for example, surgery or radiation, and which can be followed through active monitoring. Prostate cancer is the most common form of cancer in men in both Europe and the USA, which makes the market extensive, with the USA as the largest single market. Prostatype Genomics offers a genetic test that aims to improve risk stratification in prostate cancer. How do you view the clinical utility and commercial potential for the test going forward? The clinical utility is clear. A relatively small proportion of patients diagnosed with prostate cancer die from the disease, but at the same time, many patients undergo radical treatment unnecessarily. This leads to significant costs for healthcare and often lifelong side effects for patients, such as impotence and incontinence, which significantly affects the quality of life. By being better able to stratify patients based on risk, it is possible to determine who truly needs treatment and who can avoid unnecessary treatment. The decision support tools used today are often crude and create uncertainty, which leads to overtreatment, unnecessary suffering for patients, and unnecessary costs for healthcare. Prostatype Genomics' test helps reduce this uncertainty by providing a clearer basis for treatment decisions. Read the full interview here: https://www.nordnet.dk/markedet/nyheder/56237c27-1ef4-42d6-8d22-6cabfcee8a36- ·2 päivää sittenI wondered about Analysguiden's analysis with the very low price target the other day. I have now re-read the analysis and ask myself if Analysguiden has not understood the revolutionary aspect of the Prostatype Genomics test at all – or if I am completely wrong. I have not read the new validation study itself, which Veteran Affairs has conducted, and it may well be that the study was set up and carried out in a different way, so that only the test's ability to correctly predict the disease's progression in prostate patients has been validated. But as Analysguiden has interpreted the study, they conclude – as I read their analysis – that there are many other tests on the market with which Prostatype must share the market. But for me, that is not what is revolutionary about the test. It is that the test can show who will not benefit from an operation, and that the test can therefore save millions of men worldwide from an unnecessary and often quality-of-life-destroying operation – and at the same time save society enormous sums in saved surgical costs. No existing test can do that. I base my opinion not least on the peer-reviewed research article, which demonstrated that in Sweden alone, the test could save the country 800.000.000 SEK annually. https://www.nordnet.dk/markedet/nyheder/720e63e3-77d5-40f4-ac1e-b2145b43d4de. An incredibly large potential seen globally. Is there anyone wiser than me who thinks I have misread the test's potential? Or is it just Analysguiden clowning around and ending up with a ridiculous price target of 3 SEK?·1 päivä sittenThe observations of the thread starter have been mentioned in several threads. The analysis has not mentioned that the purpose is to avoid operations. It has also not mentioned that urologists see little value in the established tests, and order for approximately one third of the patients who are entitled to have it covered. There could be a turnover of tests for 2 billion/year, and an uncovered market of 4 billion SEK/year. Follow-up testing of patients who have had active surveillance or treatment, are other markets, for similar products. 14% of the patients are in the low-risk group, and do not need treatment. 46% of the patients are in the low-risk group, and will not die for another 8 years. It is assumed to be significant for urologists to be able to avoid 14% of operations and postpone 46% initially. The Gothenburg study, which dates back 25 years, has also not been mentioned.
- ·2 päivää sitten · MuokattuIt's a bit hard to believe that the increase can just continue when looking at the percentage increase this year. It helps a little bit to compare with the share price development in Saniona with 275 % in one year and 650 % in 3 years. And Saniona continues to rise steadily. And Cantargia's increase this year of 225%. (Unfortunately, I didn't dare to hold on to Saniona and sold everything, far too cheaply compared to the price a month later.)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
84 päivää sittenUutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·19 t sitten · MuokattuInterview with CEO, dated: For those unfamiliar with Prostatype Genomics – can you briefly describe the company, your business model, and the role you play in prostate cancer diagnostics and precision medicine? Prostatype Genomics is a company that originated as a spin-off from Karolinska Institutet in Stockholm and is active in precision medicine with a focus on prostate cancer. Our product is used after prostate cancer has been diagnosed and addresses one of the biggest clinical challenges globally: to determine which patients need to be treated with, for example, surgery or radiation, and which can be followed through active monitoring. Prostate cancer is the most common form of cancer in men in both Europe and the USA, which makes the market extensive, with the USA as the largest single market. Prostatype Genomics offers a genetic test that aims to improve risk stratification in prostate cancer. How do you view the clinical utility and commercial potential for the test going forward? The clinical utility is clear. A relatively small proportion of patients diagnosed with prostate cancer die from the disease, but at the same time, many patients undergo radical treatment unnecessarily. This leads to significant costs for healthcare and often lifelong side effects for patients, such as impotence and incontinence, which significantly affects the quality of life. By being better able to stratify patients based on risk, it is possible to determine who truly needs treatment and who can avoid unnecessary treatment. The decision support tools used today are often crude and create uncertainty, which leads to overtreatment, unnecessary suffering for patients, and unnecessary costs for healthcare. Prostatype Genomics' test helps reduce this uncertainty by providing a clearer basis for treatment decisions. Read the full interview here: https://www.nordnet.dk/markedet/nyheder/56237c27-1ef4-42d6-8d22-6cabfcee8a36
- ·2 päivää sittenI wondered about Analysguiden's analysis with the very low price target the other day. I have now re-read the analysis and ask myself if Analysguiden has not understood the revolutionary aspect of the Prostatype Genomics test at all – or if I am completely wrong. I have not read the new validation study itself, which Veteran Affairs has conducted, and it may well be that the study was set up and carried out in a different way, so that only the test's ability to correctly predict the disease's progression in prostate patients has been validated. But as Analysguiden has interpreted the study, they conclude – as I read their analysis – that there are many other tests on the market with which Prostatype must share the market. But for me, that is not what is revolutionary about the test. It is that the test can show who will not benefit from an operation, and that the test can therefore save millions of men worldwide from an unnecessary and often quality-of-life-destroying operation – and at the same time save society enormous sums in saved surgical costs. No existing test can do that. I base my opinion not least on the peer-reviewed research article, which demonstrated that in Sweden alone, the test could save the country 800.000.000 SEK annually. https://www.nordnet.dk/markedet/nyheder/720e63e3-77d5-40f4-ac1e-b2145b43d4de. An incredibly large potential seen globally. Is there anyone wiser than me who thinks I have misread the test's potential? Or is it just Analysguiden clowning around and ending up with a ridiculous price target of 3 SEK?·1 päivä sittenThe observations of the thread starter have been mentioned in several threads. The analysis has not mentioned that the purpose is to avoid operations. It has also not mentioned that urologists see little value in the established tests, and order for approximately one third of the patients who are entitled to have it covered. There could be a turnover of tests for 2 billion/year, and an uncovered market of 4 billion SEK/year. Follow-up testing of patients who have had active surveillance or treatment, are other markets, for similar products. 14% of the patients are in the low-risk group, and do not need treatment. 46% of the patients are in the low-risk group, and will not die for another 8 years. It is assumed to be significant for urologists to be able to avoid 14% of operations and postpone 46% initially. The Gothenburg study, which dates back 25 years, has also not been mentioned.
- ·2 päivää sitten · MuokattuIt's a bit hard to believe that the increase can just continue when looking at the percentage increase this year. It helps a little bit to compare with the share price development in Saniona with 275 % in one year and 650 % in 3 years. And Saniona continues to rise steadily. And Cantargia's increase this year of 225%. (Unfortunately, I didn't dare to hold on to Saniona and sold everything, far too cheaply compared to the price a month later.)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr, FactSet| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 26.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 7.11.2025 | |
| 2025 Q2 -tulosraportti | 23.7.2025 | |
| 2024 Q4 -tulosraportti | 13.2.2025 | |
| 2024 Q2 -tulosraportti | 26.7.2024 | |
| 2023 Q4 -tulosraportti | 15.2.2024 |
2025 Q3 -tulosraportti
84 päivää sittenUutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr, FactSet| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 26.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 7.11.2025 | |
| 2025 Q2 -tulosraportti | 23.7.2025 | |
| 2024 Q4 -tulosraportti | 13.2.2025 | |
| 2024 Q2 -tulosraportti | 26.7.2024 | |
| 2023 Q4 -tulosraportti | 15.2.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·19 t sitten · MuokattuInterview with CEO, dated: For those unfamiliar with Prostatype Genomics – can you briefly describe the company, your business model, and the role you play in prostate cancer diagnostics and precision medicine? Prostatype Genomics is a company that originated as a spin-off from Karolinska Institutet in Stockholm and is active in precision medicine with a focus on prostate cancer. Our product is used after prostate cancer has been diagnosed and addresses one of the biggest clinical challenges globally: to determine which patients need to be treated with, for example, surgery or radiation, and which can be followed through active monitoring. Prostate cancer is the most common form of cancer in men in both Europe and the USA, which makes the market extensive, with the USA as the largest single market. Prostatype Genomics offers a genetic test that aims to improve risk stratification in prostate cancer. How do you view the clinical utility and commercial potential for the test going forward? The clinical utility is clear. A relatively small proportion of patients diagnosed with prostate cancer die from the disease, but at the same time, many patients undergo radical treatment unnecessarily. This leads to significant costs for healthcare and often lifelong side effects for patients, such as impotence and incontinence, which significantly affects the quality of life. By being better able to stratify patients based on risk, it is possible to determine who truly needs treatment and who can avoid unnecessary treatment. The decision support tools used today are often crude and create uncertainty, which leads to overtreatment, unnecessary suffering for patients, and unnecessary costs for healthcare. Prostatype Genomics' test helps reduce this uncertainty by providing a clearer basis for treatment decisions. Read the full interview here: https://www.nordnet.dk/markedet/nyheder/56237c27-1ef4-42d6-8d22-6cabfcee8a36
- ·2 päivää sittenI wondered about Analysguiden's analysis with the very low price target the other day. I have now re-read the analysis and ask myself if Analysguiden has not understood the revolutionary aspect of the Prostatype Genomics test at all – or if I am completely wrong. I have not read the new validation study itself, which Veteran Affairs has conducted, and it may well be that the study was set up and carried out in a different way, so that only the test's ability to correctly predict the disease's progression in prostate patients has been validated. But as Analysguiden has interpreted the study, they conclude – as I read their analysis – that there are many other tests on the market with which Prostatype must share the market. But for me, that is not what is revolutionary about the test. It is that the test can show who will not benefit from an operation, and that the test can therefore save millions of men worldwide from an unnecessary and often quality-of-life-destroying operation – and at the same time save society enormous sums in saved surgical costs. No existing test can do that. I base my opinion not least on the peer-reviewed research article, which demonstrated that in Sweden alone, the test could save the country 800.000.000 SEK annually. https://www.nordnet.dk/markedet/nyheder/720e63e3-77d5-40f4-ac1e-b2145b43d4de. An incredibly large potential seen globally. Is there anyone wiser than me who thinks I have misread the test's potential? Or is it just Analysguiden clowning around and ending up with a ridiculous price target of 3 SEK?·1 päivä sittenThe observations of the thread starter have been mentioned in several threads. The analysis has not mentioned that the purpose is to avoid operations. It has also not mentioned that urologists see little value in the established tests, and order for approximately one third of the patients who are entitled to have it covered. There could be a turnover of tests for 2 billion/year, and an uncovered market of 4 billion SEK/year. Follow-up testing of patients who have had active surveillance or treatment, are other markets, for similar products. 14% of the patients are in the low-risk group, and do not need treatment. 46% of the patients are in the low-risk group, and will not die for another 8 years. It is assumed to be significant for urologists to be able to avoid 14% of operations and postpone 46% initially. The Gothenburg study, which dates back 25 years, has also not been mentioned.
- ·2 päivää sitten · MuokattuIt's a bit hard to believe that the increase can just continue when looking at the percentage increase this year. It helps a little bit to compare with the share price development in Saniona with 275 % in one year and 650 % in 3 years. And Saniona continues to rise steadily. And Cantargia's increase this year of 225%. (Unfortunately, I didn't dare to hold on to Saniona and sold everything, far too cheaply compared to the price a month later.)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt